Titusville, New Jersey, January 21, 2025 – Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA)...
Vous n'êtes pas connecté
WEDNESDAY, Jan. 22, 2025 -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants...
Titusville, New Jersey, January 21, 2025 – Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA)...
Titusville, New Jersey, January 21, 2025 – Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA)...
Johnson & Johnson medication Spravato, a ketamine-based nasal spray, was approved Tuesday by the Food and Drug Administration for use as a sole...
The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.
THURSDAY, Jan. 16, 2025 -- The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely...
THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved...
INDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has...
INDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has...
The U.S. Food and Drug Administration (FDA) has approved the bmarketing/b of 20 ZYN bnicotine pouch/b products after a bthorough scientific
PASADENA, Calif.–(BUSINESS WIRE)–Jan. 17, 2025– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food...